Skip to main content
. 2022 Aug 4;13:20406223221108391. doi: 10.1177/20406223221108391

Table 5.

Drug–food interactions for the top 20 substances for which the most pDDIs were identified.

Active ingredient Patients, N (%) Degree of drug–food interaction severity
Mild Moderate Severe
Methylprednisolone 123 (19.6%) Grapefruit, tobacco
Acetylsalicylic acid 55 (8.8%) Alcohol, food
Ibuprofen 105 (16.7%) Alcohol
Pantoprazole 178 (28.4%)
Baclofen 78 (12.4%) Alcohol
Ramipril 53 (8.5%) Alcohol Food (potassium-containing)
Bisoprolol 51 (8.1%) Alcohol, tobacco
Cannabidiol 46 (7.3%) Food (high-fat meal), grapefruit
Dronabinol 47 (7.5%) Grapefruit Alcohol, food (high-fat meal)
Torasemide 22 (3.5%)
Citalopram 33 (5.3%) Alcohol
Enoxaparin 127 (20.3%)
Hydrochlorothiazide 8 (1.3%)
Metoprolol 29 (4.6%) Alcohol, tobacco Food
Levothyroxine 82 (13.1%) Food a , grapefruit
Amlodipine 25 (4.0%) Grapefruit Alcohol
Duloxetine 21 (3.3%) Tobacco Alcohol
Zopiclone 65 (10.4%) Alcohol, food (high-fat/heavy meal)
Magnesium 65 (10.4%)
Calcium 33 (5.3%) Food b

pDFI databases often only indicate ‘food’ as an interaction partner of a drug. This usually refers to the timing of the food intake or a certain food composition such as food high in fat or potassium-containing food. Food: The timing of food intake is a factor influencing the absorption of ingested medicines. Patients, N (%): number of MS patients who have received the respective drug. pDDIs, potential drug–drug interactions; pDFI, potential drug–food interaction.

a

Dietary fibre, milk, soy products, coffee, nuts and seeds.

b

Foods high in oxalic acid (e.g. spinach or rhubarb) or phytic acid (e.g. bran and whole grains).